Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HUMATIN vs AMIKIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Hepatic coma (adjunctive therapy to reduce ammonia-forming bacteria in the gut),Diarrhea caused by enteropathogenic bacteria (e.g., Shigella, E. coli, Salmonella, Proteus, Staphylococcus, Pseudomonas aeruginosa)
Treatment of serious gram-negative bacterial infections,Infections caused by susceptible strains of Pseudomonas aeruginosa, Escherichia coli, Proteus, Klebsiella, Serratia, and Enterobacter
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Minimally absorbed from the gastrointestinal tract; systemically absorbed drug undergoes minimal hepatic metabolism.
Amikacin is not metabolized; it is excreted unchanged primarily by glomerular filtration.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
0% (negligible binding due to high polarity and minimal absorption)
0-10% (low binding to albumin).
0.2 L/kg (reflects limited distribution to extracellular fluid in absorbed fraction; primarily confined to GI tract)
0.25 L/kg in adults; higher in neonates and edema states (0.3-0.4 L/kg), indicating distribution into extracellular fluid.
Oral: ~1% (ranges 0.5-1.5% due to poor absorption from gastrointestinal tract)
IM: 100% (complete absorption); oral: <1% (not absorbed).
Reduce dose and/or extend interval based on Cr Cl: Cr Cl 50-90 m L/min: 60-90% of dose; Cr Cl 10-50 m L/min: 30-60% of dose; Cr Cl <10 m L/min: 20-30% of dose.
GFR 30-59 m L/min: extend dosing interval to every 12-24 hours; GFR 15-29 m L/min: extend to every 24-48 hours; GFR <15 m L/min: extend to every 48-72 hours or consider peritonitis dosing; adjust based on serum levels
No specific Child-Pugh based adjustments; caution in severe hepatic impairment due to potential nephrotoxicity.
No specific Child-Pugh based adjustments required; amikacin is minimally hepatically metabolized; monitor renal function as primary clearance route
For hepatic coma: 15-25 mg/kg/day orally in 4 divided doses; for infectious diarrhea: 50 mg/kg/day orally in 4 divided doses, max 4 g/day.
Neonates: 15-20 mg/kg/day IV/IM every 12-24 hours depending on gestational age; Infants and children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day
Adjust based on renal function; monitor for nephrotoxicity and ototoxicity; consider lower initial doses due to age-related renal decline.
Start with lower initial doses based on renal function; monitor renal function and serum amikacin levels closely; usual initial dose reduction to 7.5 mg/kg every 12-24 hours based on estimated GFR
No FDA black box warning.
Amikacin can cause nephrotoxicity and ototoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity (both vestibular and auditory) can occur in patients with pre-existing renal damage and in those with normal renal function treated with higher doses or for longer periods than recommended.
Ototoxicity (mainly with prolonged use or renal impairment),Nephrotoxicity,Neuromuscular blockade (use caution in patients with myasthenia gravis or receiving neuromuscular blocking agents),Superinfection with resistant organisms,Use in renal impairment may increase risk of toxicity,Not for systemic infections (poor absorption)
Neurotoxicity (ototoxicity) and nephrotoxicity; neuromuscular blockade; respiratory paralysis; cross-allergenicity among aminoglycosides; monitoring of renal function and drug levels recommended.
Hypersensitivity to paromomycin or other aminoglycosides,Intestinal obstruction,Severe ulcerative bowel lesions
Hypersensitivity to amikacin or any aminoglycoside; history of ototoxicity with prior aminoglycoside use.
No significant food interactions. Administer with meals to minimize gastrointestinal irritation.
No significant food interactions. Maintain adequate hydration. Avoid alcohol as it may worsen side effects.
FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. However, potential benefits may warrant use in pregnant women despite potential risks. Aminoglycosides can cause fetal harm when administered to a pregnant woman, including ototoxicity and nephrotoxicity. Paromomycin is poorly absorbed after oral administration, so systemic exposure is minimal. Risk is considered low, but caution is advised.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicity, ototoxicity) at doses similar to or lower than human doses. Amikacin crosses the placenta. First trimester: Risk cannot be excluded; use only if clearly needed. Second and third trimesters: Potential for fetal nephrotoxicity and ototoxicity; avoid use unless necessary for serious infections. Risk category D (positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience).
It is not known whether paromomycin is excreted in human milk after oral administration. Paromomycin is minimally absorbed systemically, so exposure to breastfed infants is expected to be low. However, because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
Amikacin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.1-0.2. After intramuscular administration of 500 mg, peak milk concentrations are about 1-2 mcg/m L. Because of low oral bioavailability (poorly absorbed from the GI tract), systemic effects in the nursing infant are unlikely. However, theoretical risk of alteration of infant gut flora and direct exposure. Use with caution, especially in premature infants or those with renal impairment. The American Academy of Pediatrics considers amikacin compatible with breastfeeding.
No dose adjustment is required during pregnancy. Paromomycin is poorly absorbed orally, and its pharmacokinetics are not significantly altered in pregnancy. However, caution is advised in patients with renal impairment or inflammatory bowel disease due to potential increased absorption.
Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, increased renal clearance) may require dose adjustments, but specific guidelines are not established. Generally, standard dosing based on actual body weight and renal function is used. Therapeutic drug monitoring is recommended, especially in third trimester or with concurrent renal impairment. Dose adjustments should be based on serum levels to maintain therapeutic efficacy while minimizing toxicity. No dose reduction is universally recommended; individualize based on renal function and clinical response.
Humatin (paromomycin) is an aminoglycoside antibiotic used primarily for intestinal amebiasis and hepatic coma. For hepatic coma, use as short-term adjunctive therapy; monitor for ototoxicity and nephrotoxicity, especially in renal impairment. Oral absorption is poor, so systemic toxicity is rare except with ulcerative bowel disease. Administer with food to reduce GI upset.
Monitor peak (20-30 mcg/m L) and trough (1-8 mcg/m L) serum levels; adjust dose based on renal function. Avoid concurrent use with other ototoxic/nephrotoxic drugs. Use extended-interval dosing (e.g., 15-20 mg/kg IV once daily) when possible. Assess for vestibular toxicity (ataxia, vertigo) and cochlear toxicity (tinnitus, high-frequency hearing loss).
Take this medication exactly as prescribed, with food to lessen stomach upset.,Complete the full course of therapy even if you feel better.,Drink plenty of fluids to maintain hydration.,Report any hearing loss, ringing in ears, dizziness, or changes in urine output immediately.,May cause diarrhea; notify your doctor if severe or persistent.
Report any hearing loss, ringing in ears, dizziness, or unsteadiness immediately.,Drink plenty of fluids to help prevent kidney damage.,Avoid taking other aminoglycosides or strong diuretics unless prescribed.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HUMATIN vs AMIKIN, answered by our medical review team.
HUMATIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.. AMIKIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HUMATIN and AMIKIN depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HUMATIN is: 15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.. The standard adult dose of AMIKIN is: 15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HUMATIN and AMIKIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HUMATIN is classified as Category C. FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational . AMIKIN is classified as Category C. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.